Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

 
• By Sten Stovall
  
Generate a summary of this article
Listen to this article
Beta

The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.

SC1608_Man-White-Board-Transaction_1200x675

Pharming NV has the opportunity to achieve profitability in 2017, three years sooner than expected by reacquiring the rights to commercialize its hereditary angioedema (HAE) treatment in North America, the firm said. The Netherlands-based specialty pharma announced Aug. 9 that it reached an agreement with Valeant Pharmaceuticals International Inc. to buy back rights to Ruconest (recombinant human C1 esterase inhibitor) in the US, Mexico and Canada for $60m upfront.

The deal will give Pharming control over the commercialization of Ruconest, which Valeant hadn’t been prioritizing given the recent upheaval...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.